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1. Introduction  
Cancer patients routinely take multiple – dietary supplements to prevent recurrence or 
chronic disease, to improve quality of life and overall health, or to reduce the adverse effects 
of cancer therapy (Gansler et al., 2008; Miller et al., 2009; Ströhle et al., 2010; Velicer & 
Ulrich, 2008). In fact, one of the most common behavior changes among cancer patients is 
the use of dietary supplements (Miller et al., 2009). 
Although cancer patients routinely use dietary supplements, there is often little 
consideration as to their safety, efficacy and potential negative effects (Cassileth et al., 2009; 
Giovannucci & Chan, 2010). In fact, some data suggest that higher than recommended doses 
of some vitamins and minerals might result in enhancement of carcinogenesis, changes in 
survival in some cancers and interference with therapy or prescription medications 
(Cassileth et al., 2009; Giovannucci & Chan, 2010). Nonetheless, several potentially beneficial 
effects of dietary supplements have been recorded, including reductions in the risk of cancer 
carcinogenesis and tumor progression, enhancement of immune responses against cancers 
or immune systems in general, improvements in nutrition and general health, and 
reductions in the adverse effects of cancer therapy (Cassileth et al., 2009; Doyle et al., 2006; 
Isenring et all, 2010; Miller et al., 2009; Conklin, 2000; Nicolson & Conklin, 2008; Nicolson, 
2010; Ströhle et al., 2010),  
This review will concentrate on one particularly troublesome aspect of cancer and cancer 
therapy—cancer-associated fatigue. 
2. The importance of cancer-associated fatigue 
Cancer-associated fatigue adds considerably to cancer morbidity (Brown & Kroenke, 2009; 
Hofman et al., 2007). It exists in all types of cancers from the least to the most progressed 
cancers (Brown & Kroenke, 2009; Hofman et al., 2007). Along with pain and nausea, it is one 
of the most common and troublesome symptoms of cancer (Hofman et al., 2007; Prue et al., 
2006), especially in advanced cancers (Curt et al., 2000; Prue et al., 2006; Respini et al., 2003).  
In patients receiving adjuvant therapies the prevalence of cancer-associated fatigue is 
reported to be as high as 95% (Sood & Moynihan, 2005). Thus cancer-associated fatigue is a 
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problem before, during and after therapy and can continue to be a problem years after 
cancer treatment (Curt et al., 2000; Hofman et al., 2007). Cancer-associated fatigue has a very 
strong negative effect on quality of life; therefore, addressing and reducing cancer-
associated fatigue should be an important consideration in the treatment of cancer (Curt et 
al., 2000; Nicolson, 2010). 
Although not well understood, cancer-associated fatigue is thought to be a combination of 
the effects of having cancer plus the effects of cancer treatments (Curt et al., 2000; Hofman et 
al., 2007). Unfortunately, cancer-associated fatigue is rarely treated, and is often thought to 
be an unavoidable symptom (Brown & Kroenke, 2009; Hofman et al., 2007).  
Cancer-associated fatigue can be considered to be the product of a variety of contributing 
factors (Ahlberg et al., 2003). In addition to a decrease in the availability of cellular energy, 
there are psychological factors, such as the presence of depression, anxiety, sleep 
disturbances, among others, as well as anemia, endocrine changes, poor nutritional status, 
release of inflammatory cytokines and cancer therapy that can all contribute to cancer-
associated fatigue (Ahlberg et al., 2003; Gutstein, 2001; Manzullo & Escalante, 2002; Sood & 
Moynihan, 2005). Thus cancer-associated fatigue does not occur as an isolated symptom; 
rather, it occurs as one of multiple symptoms that are present in cancer patients. Similar to 
some other symptoms in cancer patients, the severity of cancer-associated fatigue correlates 
with decreased functional abilities (Given et al., 2001).  
Cancer therapy also contributes to cancer-associated fatigue (Sood & Moynihan, 2005). In 
fact, the most commonly found and disabling effect of cancer therapy is fatigue (Given et al., 
2001; Sood & Moynihan, 2005; Vogelzang et al., 1997). During cancer therapy fatigue 
problems can vary, from mild to severe, and excess fatigue during cancer therapy is a 
significant reason why patients discontinue therapy (Liu et al., 2005). Reviewing articles on 
the effects of cancer therapy on fatigue, it was noted that 80-96% of patients receiving 
chemotherapy and 60-93% receiving radiotherapy experienced moderate to severe fatigue, 
and fatigue continued for months to years after cancer therapy ended (Manzullo & 
Escalante, 2002). Therefore, in cancer patients controlling cancer-associated fatigue as well as 
therapy-induced fatigue are both important strategies (Marrow, 2007).  
There have been efforts at understanding and treating cancer-associated fatigue as well as 
developing ways to distinguish between depression and cancer-associated fatigue (Brown & 
Kroenke, 2009). Both cancer-associated fatigue and depression have multidimensional and 
heterogeneous qualities, possessing physical, cognitive and emotional dimensions and a 
certain degree of overlap across these dimensions (Brown & Kroenke, 2009; Sood & 
Moynihan, 2005). In cancer patients fatigue or loss of energy is a core aspect of diagnosing 
depression—thus both fatigue and depression are often diagnosed together. This is usually 
accomplished by self-assessment, where fatigue and depression are considered to be part of 
a clinical symptom cluster, co-morbitity or syndrome (Arnold, 2008; Bender et al., 2008). 
There are techniques, moreover, that can distinguish between these two different symptoms 
by removal of fatigue-associated assessments from an analysis of depression (Smets et al., 
1996; Stone et al., 2000). When assessing fatigue or cancer-associated fatigue, criteria have 
been established that take depression into consideration, and these two symptoms can thus 
be separated out by considering unshared properties (Cella et al., 2001). 
Chronic or intractable fatigue lasting more than 6 months that is not reversed by normal 
sleep is the most common complaint of patients seeking general medical care (Kroenke et 
al., 1988; Morrison, 1980). It occurs naturally during aging and is also an important 
secondary condition in many clinical diagnoses (Kroenke et al., 1988; McDonald et al., 1993). 
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Most fatigued patients understand fatigue as a loss of energy and inability to perform even 
simple tasks without exertion. Many medical conditions are associated with fatigue, 
including respiratory, coronary, musculoskeletal, and bowel conditions as well as infections 
(Kroenke et al., 1988; McDonald et al., 1993; Morrison, 1980). However, this symptom is 
especially important in the overwhelming majority of cancer patients (Ahlberg et al., 2003; 
Curt et al., 2000; Hofman et al., 2007; Sood, & Moynihan, 2005).  
3. Oxidative stress and damage to mitochondrial membranes – Relationship 
to fatigue 
Another phenomenon associated with cancer and its progression as well as aging and age-
related degenerative diseases is oxidative stress (Dreher & Junod,1996; Halliwell, 1996; 
Kehrer, 1993). Oxidative stress is caused by an intracellular excess of reactive oxygen (ROS) 
and nitrogen (RNS) free radical species over intracellular antioxidants. When this imbalance 
occurs, it results in oxidation of cellular structures, such as membrane lipids and proteins, 
and mutation of mitochondrial and nuclear DNA (Abidi & Ali, 1999; Bartsch & Nair, 2004; 
Marnett, 2000; Stadtman, 2002). ROS and RNS are naturally occurring cellular free radical 
oxidants that are usually present in low concentrations and are involved in gene expression, 
intracellular signaling, cell proliferation, antimicrobial defense and other normal cellular 
processes (Castro & Freeman, 2001; Ghaffari, 2008; Johnson et al., 1996). However, when 
ROS/RNS are in excess over cellular antioxidants, damage can occur to cellular structures 
(Abidi & Ali, 1999; Castro & Freeman, 2001; Ghaffari, 2008; Maes & Twisk, 2009). Recently 
Maes (2009) has proposed a link between excess oxidative stress (and activation of 
ROS/RNS pathways and fatigue and fatiguing illnesses. 
Under normal physiological conditions our cellular antioxidant defenses usually maintain 
ROS/RNS at appropriate concentrations that prevent excess oxidation of cellular structures 
(Barber & Harris, 1994; Fridovich,1995; Sun, 1990). Endogenous cellular antioxidant defenses 
include glutathione peroxidase, catalase and superoxide dismutase, among other enzymes 
(Jagetia et al., 2003; Seifried et al., 2003), and low molecular weight dietary antioxidants 
(Aeschbach et al., 1994; Schwartz,1996). Some of these dietary antioxidants have been used 
as natural chemopreventive agents to shift the excess concentrations of oxidative molecules 
towards more physiological levels (Prasad et al., 200; Tanaka, 1994). 
Excess oxidative stress (or primarily its mediators—excess ROS/RNS) within cancer cells 
has been linked to promotion and progression of malignancy of cancers (Brown & Bicknell, 
2001; Klaunig & Kamendulis, 2004; Ray et al., 2000; Tas et al., 2005; Toyokuni et al., 1995). 
Thus oxidative stress and antioxidant status have been examined in various malignant 
cancers, such as breast (Brown & Bicknell, 2001; Kang, 2002; Ray et al., 2000; Tas et al., 2005), 
prostate (Aydin et al., 2006; Sikka, 2003), colorectal (Otamiri & Sjodahl,1989; Oxdemirler et 
al., 1989), renal (Asal et al., 1990; Gago-Dominguez et al., 2002), and other malignancies 
(Batcioglu et al., 2006; Manoharan et al., 2005; Seril et al., 2003). In all of these cancers 
ROS/RNS were in excess of antioxidant concentrations, resulting in cellular oxidative stress. 
Thus these cancers could possibly have been induced as a consequence of excess ROS/RNS 
and oxidative damage to the genetic apparatus (Abidi & Ali, 1999; Dreher & Junod, 1996; 
Jaruga et al., 1992). Even more likely than carcinogenesis is the promotion of progression of 
tumors that might not evolve to malignancy in the absence of excess oxidative stress 
(Nicolson, 2010; Nicolson & Conklin, 2008). 
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4. Cancer therapy causes excess oxidative stress and severe fatigue  
The most common therapies used against cancers, such as chemotherapy, can result in the 
generation of excess ROS/RNS (Conklin, 2000; 2004). Thus cancer therapy and the resulting 
production of excess oxidative stress can damage biological systems other than tumors 
(Conklin, 2004; Nicolson, 2010; Nicolson & Conklin, 2008). During chemotherapy the highest 
known levels of oxidative stress are generated by anthracycline antibiotics, followed (in no 
particular order) by alkylating agents, platinum-coordination complexes, 
epipodophyllotoxins, and camptothecins (Conklin, 2004). The primary site of ROS/RNS 
generation during cancer chemotherapy is the cytochrome P450 monooxygenase system 
within liver microsomes. Enzyme systems such as the xanthine-xanthine oxidase system, and 
non-enzymatic mechanisms (Fenton and Haber-Weiss reactions) also play a role in creating 
excess oxidative stress during chemotherapy. The very high levels of oxidative stress caused 
by anthracyclines are also related to their ability to displace coenzyme Q10 (CoQ10) from the 
electron transport system of cardiac mitochondria, resulting in diversion of electrons directly 
to molecular oxygen with the formation of superoxide radicals (Conklin, 2000; 2004). 
Although anthracyclines and other chemotherapeutic agents cause generation of high levels 
of ROS/RNS, not all chemotherapeutic agents generate excess oxidative stress. Some agents 
generate only modest amounts of ROS/RNS. Examples of this are: platinum-coordination 
complexes and camptothecins, taxanes, vinca alkaloids, anti-metabolites, such as the 
antifolates, and nucleoside and nucleotide analogues (Conklin, 2000; 2004; Nicolson & 
Conklin, 2008). Most chemotherapeutic agents do, however, generate some oxidative stress, 
as do all anti-neoplastic agents when they induce apoptosis in cancer cells. Drug-induced 
apoptosis is usually triggered by the release of cytochrome c from the mitochondrial 
electron transport chain. When this occurs, electrons are diverted from NADH 
dehydrogenase and reduced CoQ10 to oxygen, resulting in the formation of superoxide 
radicals (Betteridge, 2000; Conklin, 2000). 
Use of chemotherapeutic agents to treat cancer causes oxidative stress that produces side 
effects, including fatigue. This can reduce the efficacy of therapy (Nicolson & Conklin, 2008; 
Nicolson, 2010). Many anti-neoplastic agents have clearly established mechanisms of action 
that are not dependent upon the generation of ROS/RNS; however, these drugs can only 
mediate their anticancer effects on cancer cells that exhibit unrestricted progression through 
the cell cycle and have intact apoptotic pathways. Oxidative stress interferes with cell cycle 
progression by inhibiting the transition of cells from the G0 to G1 phase, slowing progression 
through S phase by inhibition of DNA synthesis, inhibiting cell cycle progression of G1 to S 
phase, and by checkpoint arrest (Balin et al., 1978; Gonzalez, 1992; Hauptlorenz et al., 1985; 
Kurata, 2000; Schackelford et al., 2000). 
Chemotherapeutic agents can also activate DNA repair systems. DNA repair of damage 
caused by alkylating agents and platinum complexes results in resistance to these drugs, 
and checkpoint arrest during oxidative stress can enhance the repair processes and diminish 
the efficacy of treatment (Fojo, 2001; Wei et al., 2000; Zhen et al., 1992). Abolishing 
checkpoint arrest produces the opposite effect and enhances the cytotoxicity of 
antineoplastic agents. By reducing oxidative stress, antioxidants counteract the effects of 
chemotherapy-induced oxidative stress on the cell cycle and enhance the cytotoxicity of 
antineoplastic agents (Conklin, 2004). 
Oxidative stress can affect important intracellular signal transduction pathways that are 
necessary for the action of some antineoplastic agents (Conklin, 2004; Hampton et al., 1998; 
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Shacter et al., 2000). There are two major pathways of drug-induced apoptosis following 
cellular damage by antineoplastic agents: the mitochondrial pathway, initiated by release of 
cytochrome c, and the CD95 death receptor pathway, initiated by CD95L binding to its 
death receptor (Fojo, 2001). Oxidative stress during chemotherapy results in the generation 
of highly electrophilic aldehydes that have the ability to bind to the nucleophilic active sites 
of caspases as well as the extracellular domain of the CD95 death receptor. This inhibits 
caspase activity and the binding of CD96L ligand, and this results in the impairment of the 
ability of antineoplastic agents to initiate apoptosis (Chandra et al., 2000; Hampton et al., 
1998; Shacter et al., 2000). 
In addition to chemotherapy, radiotherapy also results in generation of oxidative stress and 
excess ROS/RNS (Feinendegen et al., 2007; Greenberger et al., 2001). The principal target of 
radiation is tumor cell DNA, and this can be directly damaged by radiation. However, 
genetic damage is also mediated by excess ROS/RNS (Epperly et al., 2003; Feinendegen et 
al., 2007). Recently the principal source of excess ROS/RNS during radiotherapy has been 
shown to be the mitochondria (Epperly et al., 2003; Sabbarova & Kanai, 2007). The initial 
cytotoxicity of radiation is now thought to be due to excess ROS/RNS triggering of 
apoptosis via alteration of mitochondrial metabolism. This causes transiently opening of 
mitochondrial permeability transition pores, which increases the influx of calcium ions into 
the matrix. The influx of calcium ions stimulates mitochondrial nitric oxide synthase and 
generation of nitric oxide, which inhibits the respiratory chain and eventually stimulates 
excess ROS/RNS free radicals that initiate apoptosis (Leach et al., 2002; Sabbarova & Kanai, 
2007). 
5. Cancer therapy and mitochondrial damage 
Cancer therapy is associated with several adverse side effects. One of the most difficult side 
effects is caused by chemotherapeutic drug damage to mitochondria (Conklin, 2000; 
Nicolson & Conklin, 2008). Cardiac mitochondria are especially sensitive to certain 
chemotherapy agents, such as anthracycline antibiotics (Conklin, 2004). Anthracycline-
induced cardiac toxicity is characterized by acute, reversible toxicity that causes 
electrocardiographic changes and depressed myocardial contractility and by chronic, 
irreversible, dose-related cardiomyopathy (Conklin, 2004; 2005). The selective anthracycline-
induced toxicity to cardiac cells is due to damage of cardiac mitochondria. The sensitivity of 
cardiac cells to anthracyclines, such as doxorubicin, has been found to be due to the unique 
properties of cardiac mitochondria in that they possess a Complex I-associated NADH 
dehydrogenase in the inner mitochondrial membrane facing the cytosol (Lehninger, 1951; 
Rasumssen & Rasmussen, 1985). 
Doxorubicin is a relatively small molecule, and because of this property it readily penetrates 
the outer mitochondrial membrane. However, because it is hydrophilic and cannot partition 
into the lipid membrane matrix, it cannot penetrate the inner mitochondrial membrane 
(Conklin, 2005; Nohl, 1987). Thus, it cannot participate in oxidation-reduction reactions with 
the type of inner matrix-facing, electron transport chain dehydrogenases found in most 
types of cells, including most tumor cells (Conklin, 2005; Nohl, 1987). But in heart cells 
doxorubicin can interact with the mitochondrial cytosolic-facing NADH dehydrogenase that 
is unique to this tissue (Davies & Doroshow, 1986; Doroshow & Davies, 1986). This 
interaction produces doxorubicin aglycones, which are highly lipid soluble and readily 
penetrate the inner mitochondrial membrane (Conklin, 2005; Gille & Nohl, 1997). At this 
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location they can displace CoQ10 from the electron transport chain (Conklin, 2005; Davies & 
Doroshow, 1986).  
The displacement of CoQ10 from the electron transport chain during doxorubicin treatment 
results in decreases of CoQ10 in cardiac muscle (Karlsson et al., 1986) as the plasma 
concentration of CoQ10 increases (Eaton et al., 2000). CoQ10 normally accepts electrons from 
Complexes I and II and transfers them down the electron transport chain, resulting in the 
formation of water. However, the presence of aglycones in the inner mitochondrial 
membrane and inner matrix results in the transfer the electrons directly to molecular 
oxygen, resulting in the formation of superoxide radicals (Papadopoulou & Tsiftsoglou, 
1996). Thus, doxorubicin generates a high level of oxidative stress in cardiac mitochondria, 
causing acute cardiac toxicity and damage to mitochondrial DNA (Conklin, 2005; Doroshow 
& Davies, 1986; Palmeira et al., 1991). 
Anthracycline-damaged cardiac cell mitochondria cannot sustain their function, and 
changes in their structure results in disruption of mitochondria and eventually apoptosis 
(Serrano et al., 1999; Conklin, 2005; Gille & Nohl, 1997). This produces cardiac insufficiency 
and an inability to respond to pharmacological interventions, resulting ultimately in cardiac 
failure. However, if CoQ10 is administered during anthracycline chemotherapy, damage to 
the heart is prevented by decreasing anthracycline metabolism within cardiac mitochondria 
and by competing with aglycones for the CoQ10 sites within the electron transport chain 
(Conklin, 2005). Thus, CoQ10 administered concurrently with anthracyclines can maintain 
the integrity of cardiac mitochondria and prevent damage to the heart, and at the same time 
enhancing the anti-cancer activity of anthracyclines (Conklin, 2000; 2005). 
In addition to chemotherapy, radiotherapy also produces damage to tissues other than 
cancerous tissues. Agents that protect tissues against radiation effects have been used to 
reduce unwanted damage (Brizel, 2007; Sabbarova & Kanai, 2007).  
Radioprotective agents that have been used to decrease the adverse effects of radiotherapy 
are: antioxidants, free radical scavengers, inhibitors of nitric oxide synthase and anti-
inflammatory and immunomodulatory agents (Brizel, 2007; Sabbarova & Kanai, 2007). The 
most effective of these under development target mitochondria, such as proteins and 
peptides that can be transported into mitochondria and plasmids or nucleotide sequences, 
for example, agents that target and stimulate mitochondrial manganese superoxide 
dismutase genes to produce this important dismutase have been used as radioprotective 
agents (Sabbarova & Kanai, 2007). 
6. Molecular replacement of mitochondrial components during cancer 
therapy  
As discussed in Section 5, chemotherapy can displace important mitochondrial cofactors, 
such as CoQ10 (Conklin, 2000; 2005). During chemotherapy replacement of CoQ10 
dramatically prevents development of anthracycline-induced cardiomyopathy and 
histopathological changes. It can also prevent changes in electrocardiograms (EKG) 
characteristic of anthracycline-induced heart damage (Domae et al., 1981). Indeed, the 
administration of CoQ10 to animals resulted in increased survival, improvement in the EKG 
patterns, and reduced heart histopathological changes (Usui et al., 1982). These preclinical 
data, along with clinical data (discussed in Conklin, 2004 and Nicolson & Conklin, 2008) 
support the contention that CoQ10 protects the heart tssue from anthracycline-induced 
damage. 
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During chemotherapy of cancer, patients have received concurrent administration of CoQ10. 
This can affect both acute and chronic cardiotoxicity caused by anthracyclines (Conklin, 
2004; 2005; Nicolson & Conklin, 2008). For example, Judy et al. (1984) studied the 
importance of administering CoQ10 on the development of doxorubicin-induced 
cardiotoxicity in patients with lung cancer. Doxorubicin given alone without CoQ10 caused 
marked impairment of cardiac function with a significant increase in heart rate and a 
substantial decrease in ejection fraction, stroke index and cardiac index. In contrast, 
doxorubicin administered along with CoQ10, did not cause cardiotoxicity—cardiac function 
remained unchanged. Other studies have confirmed these results and have shown that 
CoQ10 can reduce the cardiac toxicity of doxorubicin in adults (Buckingham et al., 1997; 
Cortes et al., 1978) and children (Iarussi et al., 1994; Loke et al., 2006). 
Thus in preclinical and clinical studies the data indicate that CoQ10 protects the heart from 
the cardiotoxicity of anthracyclines. The impact of CoQ10 on the anti-neoplastic efficacy of 
anthracycline-based chemotherapy, however, was not studied in these reports (Buckingham 
et al., 1997; Cortes et al., 1978; Iarussi et al., 1994; Loke et al., 2006). 
7. Cancer-associated fatigue and other cancer-associated conditions  
The most common complaint of patients undergoing anti-neoplastic therapy is fatigue, but 
there are also other complaints that include: pain, nausea, vomiting, malaise, diarrhea, 
headaches, rashes and infections (Buckingham et al., 1997; Loke et al., 2006; Manzullo & 
Escalante, 2002). Other more serious problems can also occur, such as cardiomyopathy, 
peripheral neuropathy, hepatotoxicity, pulmonary fibrosis, mucositis and other effects 
(Buckingham et al., 1997; Liu et al., 2005; Loke et al., 2006; Manzullo & Escalante, 2002). Due 
to misconceptions among patients and their physicians, most patients feel that cancer 
therapy-associated fatigue is an untreatable symptom (Vogelzang et al., 1997). Although 
fatigue is usually the most commonly reported adverse symptom during cancer therapy, up 
until recently there was little effort directed at reducing fatigue before, during or after 
cancer therapy (Von Roenn & Paice, 2005). This has changed recently (Nicolson, 2010; 
Nicolson & Conklin, 2008). 
Reducing cancer-associated fatigue and fatigue associated with cancer therapy are now 
considered important therapeutic goals. Psychological, physical, pharmaceutical and 
nutraceutical methods have been undertaken to reduce fatigue and improve the quality of 
life of cancer patients (Borneman et al., 2007; Escalante et al., 2011; Nicolson, 2010). These 
treatments are based on suppressing fatigue but also on controlling co-morbid or related 
symptoms, such as pain, anemia, cachexia, sleep disorders, depression and other symptoms 
(Escalante et al., 2011; Mustian et al., 2007; Nicolson, 2010; Ryan et al., 2007; Watson & Mock, 
2004; Zee & Acoli-Isreal, 2009). 
Unfortunately, there is no standard protocol related to treating cancer-associated fatigue 
and related symptoms. In reviewing the types of supportive measures used to control 
fatigue and related symptoms, the data suggest that graded exercise, nutritional support, 
treatment of psychological problems (such as depression with certain anti-depressants or 
psycostimulants), treatment of anemia with hematopoetic growth factors and control of 
insomnia with cognitive behavioral therapy or pharmacological and nonpharmacological 
therapies all have a role to various degrees in controlling cancer-associated fatigue 
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(Escalante et al., 2011; Mustian et al., 2007; Nicolson, 2010; Ryan et al., 2007; Watson & Mock, 
2004; Zee & Acoli-Isreal, 2009). Some of these approaches using pharmacological drugs and 
growth factors have been systematically analyzed in 27 studies (meta-analysis) by Milton et 
al. (2008). In this limited analysis, only a psycostimulant (methylphenidate) and 
hematopoetic growth factors (erythropoietin and darbopeitin) were more effective than 
placebo treatments. Other treatments were no better than placebo in the treatment of cancer-
related fatigue (Milton et al., 2008).  
8. Cancer-associated fatigue, aging and oxidative mitochondrial damage  
Cancer-associated fatigue has been defined as a multidimensional sensation (McDonald et 
al., 1993; Milton et al., 2008; Mustian et al., 2007; Ryan et al., 2007). Most patients understand 
fatigue as a loss of energy and inability to perform even simple tasks without exertion 
(Levy, 2008; Milton et al., 2008). Cancer-associated fatigue has been described as the 
dysregulation of several interrelated physiological, biochemical and psychological systems 
(Mustian et al., 2007; Ryan et al., 2007), but at the tissue and cellular levels fatigue is related 
to reductions in the efficiency of cellular energy systems, mainly found in mitochondria 
(Agadjanyan et al., 2003; Nicolson, 2003; 2005). Damage to mitochondrial components, 
mainly by ROS/RNS oxidation, can impair mitochondrial function, and this can also result 
in oxidative damage (reviewed in Bartsch & Nair, 2004; Castro & Freeman, 2001; Kehrer, 
1993). Mitochondrial membranes and DNA are major targets of oxidative stress, and with 
aging ROS/RNS mitochondrial damage can accumulate (Huang & Manton, 2004; Wei & 
Lee, 2002). 
During aging and in certain medical conditions oxidative damage to mitochondrial 
membranes impairs mitochondrial function (Huang & Manton, 2004; Logan & Wong, 2001; 
Wei & Lee, 2002). For example, in chronic fatigue syndrome patients there is evidence of 
oxidative damage to DNA and lipids (Logan & Wong, 2001; Manuel y Keenoy et al., 2001) as 
well as oxidized blood markers (Richards et al., 2000) and muscle membrane lipids (Felle et 
al., 2000) that are indicative of excess oxidative stress (Dianzani, 1993). In chronic fatigue 
syndrome patients also have sustained elevated levels of peroxynitrite due to excess nitric 
oxide, which can result in lipid peroxidation and loss of mitochondrial function as well as 
changes in cytokine levels that exert a positive feedback on nitric oxide production, 
increasing the rate of membrane damage (Pall, 2000).  
9. Molecular replacement of oxidized membrane components and its effect 
on fatigue  
In cancer patients mitochondrial membranes as well as other cellular membranes are 
especially sensitive to oxidative damage by ROS/RNS, which occurs at high rates in cancer 
(Batcioglu et al., 2006; Dianzani, 1993; Gago-Dominguez et al., 2002; Manoharan et al., 2005; 
Otamiri & Sjodahl, 1989; Oxdemirler et al., 1989; Seril et al., 2003). Oxidation of membrane 
phospholipids alters their structure, affecting lipid fluidity, permeability and membrane 
function (Dianzani, 1993; Nicolson et al., 1977; Subczynski & Wisniewska, 2000). One of the 
most important events caused by ROS/RNS damage is loss of electron transport function, 
and this appears to be related to mitochondrial membrane lipid peroxidation. Membrane 
oxidation induces permeability changes in mitochondria, and this can cause loss of 
www.intechopen.com
Nutritional Supplements for Cancer-Associated Fatigue and 
Cancer Therapy – A Molecular Basis for Restoring Mitochondrial Function 
 
155 
mitochondrial transmembrane potential, an essential requirement of oxidative 
phosphorylation (Kanno et al., 2004; Radi et al., 1994). 
Lipid Replacement Therapy (Nicolson, 2003; 2005; 2010) has been used to reverse the 
accumulation of damaged lipids in mitochondria and other cellular membranes. Lipid 
Replacement Therapy plus antioxidants can reverse ROS/RNS damage and increase 
mitochondrial function in certain fatiguing disorders, such as chronic fatigue, chronic 
fatigue syndrome and fibromyalgia syndrome. Lipid Replacement Therapy has been 
found to be effective in preventing ROS/RNS-associated changes and reversing 
mitochondrial damage and loss of function (reviewed in Nicolson, 2010; Nicolson & 
Ellithrope, 2006). 
Lipid Replacement Therapy with unoxidized lipid and antioxidant supplements has been 
effective in replacement of damaged cellular and mitochondrial membrane phospholipids 
and other lipids that are essential structural and functional components of all biological 
membranes (reviewed in Nicolson, 2010; Nicolson & Ellithrope, 2003). NTFactor, a Lipid 
Replacement oral supplement containing phospholipids, phosphoglycolipids, cardiolipid 
precursors and other membrane lipids, has been used successfully in animal and clinical 
lipid replacement studies (Agadjanyan et al., 2003; Ellithorpe et al., 2003; Nicolson & 
Ellithorpe, 2006; Nicolson et al., 2010). NTFactor's encapsulated lipids are protected from 
oxidation in the gut and can be absorbed and transported into tissues via lipid carriers 
without oxidation. Once inside cells the membrane lipids naturally replace oxidized, 
damaged membrane lipids by natural diffusion, and carrier proteins pick up the damaged 
lipids for degradation, transport and excretion (Mansbach & Dowell, 2000). 
In preclinical studies NTFactor has been used to reduce age-related functional damage. 
Using rodents Seidman et al. (2002) found that NTFactor prevented hearing loss associated 
with aging and shifted the threshold hearing from 35-40 dB in control, aged rodents to 13-17 
dB. They also found that NTFactor preserved cochlear mitochondrial function and 
prevented aging-related mitochondrial DNA deletions found in the cochlear. Thus NTFactor 
was successful in preventing age-associated hearing loss and reducing mitochondrial 
damage and DNA deletions in rodents (Seidman et al. 2002). 
In clinical studies Lipid Replacement Therapy has been used to reduce fatigue and protect 
cellular and mitochondrial membranes from oxidative damage by ROS/RNS (reviewed in 
Nicolson, 2003; 2005; 2010). A vitamin supplement mixture containing NTFactor was by 
used by Ellithorpe et al. (2003) in a study of patients with severe chronic fatigue and was 
found to reduce their fatigue by approximately 40.5% in 8 weeks. In these studies fatigue 
was monitored by use of the Piper Fatigue Scale to measure clinical fatigue and quality of 
life (Piper et al., 1987). In addition, in a subsequent study we examined the effects of 
NTFactor on fatigue and mitochondrial function in patients with chronic fatigue 
(Agadjanyan et al., 2003). Oral administration of NTFactor for 12 weeks resulted in a 35.5% 
reduction in fatigue and 26.8% increase in mitochondrial function; whereas after a 12-week 
wash-out period fatigue increased and mitochondrial function decreased back towards 
control levels (Agadjanyan et al., 2003). Thus in fatigued subjects dietary Lipid Replacement 
Therapy can significantly improve and even restore mitochondrial function and 
significantly decrease fatigue. Similar findings were observed in chronic fatigue syndrome 
and fibromyalgia syndrome patients (Nicolson & Ellithorpe, 2003). Recently a new 
formulation of NTFactor plus vitamins, minerals and other supplements resulted in a 36.8% 
reduction in fatigue within one week (Nicolson et al., 2010) (Table 1). 
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Table 1. Effects of dietary Lipid Replacement supplement NTFactor on Piper Fatigue Scale 
scores. 
10. Lipid replacement therapy in conjunction with cancer therapy 
Lipid Replacement Therapy has been used to reduce the adverse effects of chemotherapy in 
cancer patients (Nicolson, 2010). For example, a vitamin-mineral mixture with NTFactor has 
been used in cancer patients to reduce some of most common adverse effects of cancer 
therapy, such as chemotherapy-induced fatigue, nausea, vomiting, malaise, diarrhea, 
headaches and other side effects (Colodny et al., 2000). In two studies on patients with 
advanced metastatic colon, pancreatic or rectal cancers receiving a 12-week chemotherapy 
treatment schedule of 5-florouracil/methotrexate/leukovorin Lipid Replacement Therapy 
was used to reduce adverse effects of chemotherapy.  
In the first unblinded part of the clinical study the effectiveness of NTFactor in a vitamin-
mineral mixture administered before and during chemotherapy was determined by examining 
signs and symptoms, and in particular, the side effects of therapy. A quality of life evaluation 
was conducted by a research nurse, and it was determined that patients on NTFactor 
supplementation experienced significantly fewer episodes of fatigue, nausea, diarrhea, 
constipation, skin changes, insomnia and other side effects (Colodny et al., 2000). In this open 
label trial 81% of patients demonstrated an overall improvement in quality of life parameters 
while on chemotherapy with Lipid Replacement Therapy (Colodny et al., 2000).  
In the double-blinded, cross-over, placebo-controlled, randomized part of the study on 
advanced cancers the patients on chemotherapy plus Lipid Replacement Therapy showed 
improvements in signs/symptoms associated with the adverse effects of chemotherapy 
(Colodny et al., 2000). Adding Lipid Replacement resulted in improvements in the incidence 
of fatigue, nausea, diarrhea, impaired taste, constipation, insomnia and other quality of life 
indicators. Following cross-over from the placebo arm to the Lipid Replacement Therapy 
arm, 57-70% of patients on chemotherapy reported improvements in nausea, impaired taste, 
tiredness, appetite, sick feeling and other quality of life indicators (Colodny et al., 2000) 
(Table 2). This clinical trial and other data clearly demonstrated the usefulness of Lipid 
Replacement Therapy given during chemotherapy to reduce the adverse effects of cancer 
therapy (Nicolson, 2010).  
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     Average % patients on test arm# 
First arm   Second arm improvement no change  worsening 
_________________________________________________________________________________ 
placebo      Propax(+NTFactor)  57      22     21 
 
Propax(+NTFactor) placebo   70       6      24 
_________________________________________________________________________________ 
Table modified from Nicolson (2010). 
* The same regimen of 5-flurouracil/methotrexate/leukovoran was used for colon, pancreatic or rectal 
cancers. 
#The percent of patients’ self-reporting adverse effects was averaged with the percent of patients with 
adverse effects reported by a research nurse. 
_________________________________________________________________________________ 
Table 2. Effects of Propax with NTFactor on the adverse effects of chemotherapy in a cross-
over trial. 
11. Summary – Cancer-sssociated fatigue and its treatment 
Nutritional supplements have been used in a variety of diseases to provide patients with a 
natural, safe alternative to pharmacological drugs. In patients with cancer nutritional 
supplements are often used for specific purposes or to improve quality of life. For example, 
cancer-associated fatigue is one of the most common symptoms in all forms and stages of 
cancer, but few patients receive assistance for their fatigue. Cancer-associated fatigue is 
associated with cellular oxidative stress, and during cancer therapy excess drug-induced 
oxidative stress can cause a number of adverse effects, including: fatigue, nausea, vomiting 
and more serious effects. Cancer-associated fatigue and the adverse effects of cancer therapy 
can be reduced with Lipid Replacement Therapy, a natural lipid supplement formulation 
that replaces damaged membrane lipids along with providing antioxidants and enzymatic 
cofactors. Administering dietary Lipid Replacement Therapy can reduce oxidative 
membrane damage and restore mitochondrial and other cellular functions. Recent clinical 
trials using cancer and non-cancer patients with chronic fatigue have shown the benefits of 
specific Lipid Replacement Therapy nutritional lipid supplements in reducing fatigue and 
restoring mitochondrial function. 
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